CHRS Articles, Coherus BioSciences Inc. - From 06/05/24

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Ri...

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced that senior management ...

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selec...

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced that senior management ...

– New $38.7 million term loan with a May 2029 maturity –– $37.5 million royalty monetization financing based on future sales of LOQTORZI ...

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarte...

REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced the first presentatio...

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activati...

– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 –  – UDENYCA® net sales of $36.2 million in the fou...

REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its fourth qua...